{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:22:17Z","timestamp":1783642937243,"version":"3.55.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Metastatic progression depends upon the ability of disseminated tumor cells to evade immune surveillance. Major Histocompatibility Complex (MHC)-mediated antigen presentation facilitates T cell-dependent eradication of metastatic tumor cells. Here, we show that nuclear corepressor 2 (NCOR2) is an epigenetic regulator of MHC class I molecule presentation on breast tumor cells. Patients with triple negative breast cancer (TNBC) that express high levels of NCOR2 also exhibit reduced metastasis-free survival and decreased MHC class I expression, and the metastatic lesions in patients with TNBC have high nuclear NCOR2 and reduced Cluster of Differentiation (CD)8\n                    <jats:sup>+<\/jats:sup>\n                    T cells. Reducing NCOR2 expression or preventing its interaction with Histone Deacetylase,\u00a0HDAC3, enhances innate immune cell recruitment and activity, and elevates MHC class I levels on disseminated cancer cells to potentiate CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell activity and apoptosis induction that prevents metastatic progression. The studies provide evidence to support NCOR2 as a targetable epigenetic regulator of metastasis towards which therapies could be developed to reduce patient mortality.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-72168-3","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T18:06:36Z","timestamp":1778004396000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["NCOR2 represses MHC class I molecule expression to drive metastatic progression of breast cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Pavla","family":"Ticha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3115-2560","authenticated-orcid":false,"given":"Jason J.","family":"Northey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Narain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivang","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnathon N.","family":"Lakins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7615-2594","authenticated-orcid":false,"given":"Kelly","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair J.","family":"Ironside","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0841-9415","authenticated-orcid":false,"given":"Allison P.","family":"Drain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Zidek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin K.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunn-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9886-8542","authenticated-orcid":false,"given":"Eugene","family":"Shenderov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4786-6752","authenticated-orcid":false,"given":"Valerie M.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"72168_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41591-020-01195-4","volume":"27","author":"K Ganesh","year":"2021","unstructured":"Ganesh, K. & Massague, J. Targeting metastatic cancer. Nat. Med. 27, 34\u201344 (2021).","journal-title":"Nat. Med."},{"key":"72168_CR2","doi-asserted-by":"crossref","unstructured":"Dalla, E., Sreekumar, A., Aguirre-Ghiso, J. A. & Chodosh, L. A. Dormancy in breast cancer. Cold Spring Harb. Perspect. Med. 13, a041331 (2023).","DOI":"10.1101\/cshperspect.a041331"},{"key":"72168_CR3","doi-asserted-by":"crossref","unstructured":"Ruggieri, L. et al. Host-related factors in the interplay among inflammation, immunity and dormancy in breast cancer recurrence and prognosis: an overview for clinicians. Int. J. Mol. Sci. 24, 4974 (2023).","DOI":"10.3390\/ijms24054974"},{"key":"72168_CR4","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1158\/0008-5472.CAN-21-1407","volume":"81","author":"JA Aguirre-Ghiso","year":"2021","unstructured":"Aguirre-Ghiso, J. A. Translating the Science of Cancer Dormancy to the Clinic. Cancer Res. 81, 4673\u20134675 (2021).","journal-title":"Cancer Res"},{"key":"72168_CR5","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s43018-020-0088-5","volume":"1","author":"E Risson","year":"2020","unstructured":"Risson, E., Nobre, A. R., Maguer-Satta, V. & Aguirre-Ghiso, J. A. The current paradigm and challenges ahead for the dormancy of disseminated tumor cells. Nat. Cancer 1, 672\u2013680 (2020).","journal-title":"Nat. Cancer"},{"key":"72168_CR6","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.3389\/fimmu.2020.02166","volume":"11","author":"A Sistigu","year":"2020","unstructured":"Sistigu, A., Musella, M., Galassi, C., Vitale, I. & De Maria, R. Tuning cancer fate: tumor microenvironment\u2019s role in cancer stem cell quiescence and reawakening. Front. Immunol. 11, 2166 (2020).","journal-title":"Front. Immunol."},{"key":"72168_CR7","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1158\/0008-5472.CAN-19-0458","volume":"79","author":"DR Welch","year":"2019","unstructured":"Welch, D. R. & Hurst, D. R. Defining the hallmarks of metastasis. Cancer Res. 79, 3011\u20133027 (2019).","journal-title":"Cancer Res."},{"key":"72168_CR8","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature20785","volume":"540","author":"H Hosseini","year":"2016","unstructured":"Hosseini, H. et al. Early dissemination seeds metastasis in breast cancer. Nature 540, 552\u2013558 (2016).","journal-title":"Nature"},{"key":"72168_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10555-022-10073-z","volume":"42","author":"K Truskowski","year":"2023","unstructured":"Truskowski, K., Amend, S. R. & Pienta, K. J. Dormant cancer cells: programmed quiescence, senescence, or both? Cancer Metastasis Rev. 42, 37\u201347 (2023).","journal-title":"Cancer Metastasis Rev."},{"key":"72168_CR10","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.4161\/cc.5.16.2995","volume":"5","author":"R Marches","year":"2006","unstructured":"Marches, R., Scheuermann, R. & Uhr, J. Cancer dormancy: from mice to man. Cell Cycle 5, 1772\u20131778 (2006).","journal-title":"Cell Cycle"},{"key":"72168_CR11","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.4161\/cc.5.16.3109","volume":"5","author":"AC Ranganathan","year":"2006","unstructured":"Ranganathan, A. C., Adam, A. P. & Aguirre-Ghiso, J. A. Opposing roles of mitogenic and stress signaling pathways in the induction of cancer dormancy. Cell Cycle 5, 1799\u20131807 (2006).","journal-title":"Cell Cycle"},{"key":"72168_CR12","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nrc2256","volume":"7","author":"JA Aguirre-Ghiso","year":"2007","unstructured":"Aguirre-Ghiso, J. A. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7, 834\u2013846 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"72168_CR13","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1189\/jlb.1107774","volume":"84","author":"MW Teng","year":"2008","unstructured":"Teng, M. W., Swann, J. B., Koebel, C. M., Schreiber, R. D. & Smyth, M. J. Immune-mediated dormancy: an equilibrium with cancer. J. Leukoc. Biol. 84, 988\u2013993 (2008).","journal-title":"J. Leukoc. Biol."},{"key":"72168_CR14","doi-asserted-by":"crossref","unstructured":"Woods, E. C. et al. A bulky glycocalyx fosters metastasis formation by promoting G1 cell cycle progression. eLife 6, e25752 (2017).","DOI":"10.7554\/eLife.25752"},{"key":"72168_CR15","doi-asserted-by":"crossref","unstructured":"Chernosky, N. M. & Tamagno, I. The role of the innate immune system in cancer dormancy and relapse. Cancers 13, 5621 (2021).","DOI":"10.3390\/cancers13225621"},{"key":"72168_CR16","doi-asserted-by":"crossref","unstructured":"Jiang, X., Liang, L., Chen, G. & Liu, C. Modulation of immune components on stem cell and dormancy in cancer. Cells 10, 2826 (2021).","DOI":"10.3390\/cells10112826"},{"key":"72168_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.semcancer.2021.02.002","volume":"78","author":"A Corthay","year":"2022","unstructured":"Corthay, A., Bakacs, T., Thangavelu, G. & Anderson, C. C. Tackling cancer cell dormancy: Insights from immune models, and transplantation. Semin. Cancer Biol. 78, 5\u201316 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"72168_CR18","first-page":"415","volume":"2","author":"CA Butts","year":"2013","unstructured":"Butts, C. A. Anti-tumor immune response in early stage non small cell lung cancer (NSCLC): implications for adjuvant therapy. Transl. Lung Cancer Res. 2, 415\u2013422 (2013).","journal-title":"Transl. Lung Cancer Res."},{"key":"72168_CR19","doi-asserted-by":"publisher","first-page":"720","DOI":"10.4143\/crt.2023.468","volume":"55","author":"HY Min","year":"2023","unstructured":"Min, H. Y. & Lee, H. Y. Cellular dormancy in cancer: mechanisms and potential targeting strategies. Cancer Res. Treat. 55, 720\u2013736 (2023).","journal-title":"Cancer Res. Treat."},{"key":"72168_CR20","first-page":"197","volume":"42","author":"F Francescangeli","year":"2023","unstructured":"Francescangeli, F. et al. Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution. Cancer Metastasis Rev. 42, 197\u2013215 (2023).","journal-title":"Cancer Metastasis Rev."},{"key":"72168_CR21","doi-asserted-by":"crossref","unstructured":"Bakhshandeh, S., Werner, C., Fratzl, P. & Cipitria, A. Microenvironment-mediated cancer dormancy: insights from metastability theory. Proc. Natl. Acad. Sci. USA 119, e2111046118 (2022).","DOI":"10.1073\/pnas.2111046118"},{"key":"72168_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.semcancer.2021.09.008","volume":"78","author":"S Attaran","year":"2022","unstructured":"Attaran, S. & Bissell, M. J. The role of tumor microenvironment and exosomes in dormancy and relapse. Semin. Cancer Biol. 78, 35\u201344 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"72168_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.semcancer.2021.06.004","volume":"78","author":"KK Payne","year":"2022","unstructured":"Payne, K. K. Cellular stress responses and metabolic reprogramming in cancer progression and dormancy. Semin. Cancer Biol. 78, 45\u201348 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"72168_CR24","doi-asserted-by":"publisher","first-page":"627023","DOI":"10.3389\/fonc.2021.627023","volume":"11","author":"Y Akkoc","year":"2021","unstructured":"Akkoc, Y., Peker, N., Akcay, A. & Gozuacik, D. Autophagy and cancer dormancy. Front. Oncol. 11, 627023 (2021).","journal-title":"Front. Oncol."},{"key":"72168_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-01883-2","volume":"21","author":"L Dai","year":"2021","unstructured":"Dai, L. et al. Fibroblasts in cancer dormancy: foe or friend?. Cancer Cell Int. 21, 184 (2021).","journal-title":"Cancer Cell Int."},{"key":"72168_CR26","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.3389\/fonc.2020.01766","volume":"10","author":"AL Parker","year":"2020","unstructured":"Parker, A. L. & Cox, T. R. The role of the ECM in lung cancer dormancy and outgrowth. Front. Oncol. 10, 1766 (2020).","journal-title":"Front. Oncol."},{"key":"72168_CR27","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s12276-020-0423-z","volume":"52","author":"SY Park","year":"2020","unstructured":"Park, S. Y. & Nam, J. S. The force awakens: metastatic dormant cancer cells. Exp. Mol. Med. 52, 569\u2013581 (2020).","journal-title":"Exp. Mol. Med."},{"key":"72168_CR28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/978-3-030-22254-3_15","volume":"1164","author":"JE Davis Jr.","year":"2019","unstructured":"Davis, J. E. Jr., Kirk, J., Ji, Y. & Tang, D. G. Tumor dormancy and slow-cycling cancer cells. Adv. Exp. Med. Biol. 1164, 199\u2013206 (2019).","journal-title":"Adv. Exp. Med. Biol."},{"key":"72168_CR29","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.cell.2013.10.029","volume":"155","author":"FG Giancotti","year":"2013","unstructured":"Giancotti, F. G. Mechanisms governing metastatic dormancy and reactivation. Cell 155, 750\u2013764 (2013).","journal-title":"Cell"},{"key":"72168_CR30","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10555-021-09964-4","volume":"40","author":"I Algarra","year":"2021","unstructured":"Algarra, I., Garrido, F. & Garcia-Lora, A. M. MHC heterogeneity and response of metastases to immunotherapy. Cancer Metastasis Rev. 40, 501\u2013517 (2021).","journal-title":"Cancer Metastasis Rev."},{"key":"72168_CR31","doi-asserted-by":"publisher","first-page":"636568","DOI":"10.3389\/fimmu.2021.636568","volume":"12","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy, K., Colbert, J. D. & Rock, K. L. Cancer immune evasion through loss of MHC class I antigen presentation. Front. Immunol. 12, 636568 (2021).","journal-title":"Front. Immunol."},{"key":"72168_CR32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/ijc.29375","volume":"138","author":"F Garrido","year":"2016","unstructured":"Garrido, F., Romero, I., Aptsiauri, N. & Garcia-Lora, A. M. Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype. Int. J. Cancer 138, 271\u2013280 (2016).","journal-title":"Int. J. Cancer"},{"key":"72168_CR33","doi-asserted-by":"publisher","first-page":"6750","DOI":"10.1158\/0008-5472.CAN-14-2406","volume":"74","author":"I Romero","year":"2014","unstructured":"Romero, I., Garrido, F. & Garcia-Lora, A. M. Metastases in immune-mediated dormancy: a new opportunity for targeting cancer. Cancer Res. 74, 6750\u20136757 (2014).","journal-title":"Cancer Res."},{"key":"72168_CR34","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.it.2023.07.005","volume":"44","author":"Y Sykulev","year":"2023","unstructured":"Sykulev, Y. Factors contributing to the potency of CD8(+) T cells. Trends Immunol. 44, 693\u2013700 (2023).","journal-title":"Trends Immunol."},{"key":"72168_CR35","doi-asserted-by":"publisher","first-page":"102345","DOI":"10.1016\/j.coi.2023.102345","volume":"83","author":"E Bawden","year":"2023","unstructured":"Bawden, E. & Gebhardt, T. The multifaceted roles of CD4(+) T cells and MHC class II in cancer surveillance. Curr. Opin. Immunol. 83, 102345 (2023).","journal-title":"Curr. Opin. Immunol."},{"key":"72168_CR36","doi-asserted-by":"publisher","first-page":"102325","DOI":"10.1016\/j.coi.2023.102325","volume":"82","author":"J Bandola-Simon","year":"2023","unstructured":"Bandola-Simon, J. & Roche, P. A. Regulation of MHC class II and CD86 expression by March-I in immunity and disease. Curr. Opin. Immunol. 82, 102325 (2023).","journal-title":"Curr. Opin. Immunol."},{"key":"72168_CR37","doi-asserted-by":"publisher","first-page":"1035363","DOI":"10.3389\/fimmu.2022.1035363","volume":"13","author":"L Santambrogio","year":"2022","unstructured":"Santambrogio, L. & Franco, A. The yin\/yang balance of the MHC-self-immunopeptidome. Front. Immunol. 13, 1035363 (2022).","journal-title":"Front. Immunol."},{"key":"72168_CR38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.crimmu.2022.05.001","volume":"3","author":"FM Ruggiero","year":"2022","unstructured":"Ruggiero, F. M. & Springer, S. Homotypic and heterotypic in cis associations of MHC class I molecules at the cell surface. Curr. Res. Immunol. 3, 85\u201399 (2022).","journal-title":"Curr. Res. Immunol."},{"key":"72168_CR39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.molimm.2021.05.009","volume":"136","author":"MLM Jongsma","year":"2021","unstructured":"Jongsma, M. L. M., Neefjes, J. & Spaapen, R. M. Playing hide and seek: Tumor cells in control of MHC class I antigen presentation. Mol. Immunol. 136, 36\u201344 (2021).","journal-title":"Mol. Immunol."},{"key":"72168_CR40","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.coi.2005.07.015","volume":"17","author":"J Trowsdale","year":"2005","unstructured":"Trowsdale, J. HLA genomics in the third millennium. Curr. Opin. Immunol. 17, 498\u2013504 (2005).","journal-title":"Curr. Opin. Immunol."},{"key":"72168_CR41","doi-asserted-by":"crossref","unstructured":"Zheng, X. et al. A novel tongue squamous cell carcinoma cell line escapes from immune recognition due to genetic alterations in HLA class I complex. Cells 12, 35 (2022).","DOI":"10.3390\/cells12010035"},{"key":"72168_CR42","doi-asserted-by":"publisher","first-page":"767","DOI":"10.4049\/jimmunol.174.2.767","volume":"174","author":"AT Kamath","year":"2005","unstructured":"Kamath, A. T., Sheasby, C. E. & Tough, D. F. Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma. J. Immunol. 174, 767\u2013776 (2005).","journal-title":"J. Immunol."},{"key":"72168_CR43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"72168_CR44","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/nbt.3344","volume":"33","author":"SA Shukla","year":"2015","unstructured":"Shukla, S. A. et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat. Biotechnol. 33, 1152\u20131158 (2015).","journal-title":"Nat. Biotechnol."},{"key":"72168_CR45","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1084\/jem.190.5.639","volume":"190","author":"H Wang","year":"1999","unstructured":"Wang, H. & Shlomchik, M. J. Autoantigen-specific B cell activation in Fas-deficient rheumatoid factor immunoglobulin transgenic mice. J. Exp. Med. 190, 639\u2013649 (1999).","journal-title":"J. Exp. Med."},{"key":"72168_CR46","doi-asserted-by":"crossref","unstructured":"Shukla, A., Cloutier, M., Appiya Santharam, M., Ramanathan, S. & Ilangumaran, S. The MHC class-I transactivator NLRC5: implications to cancer immunology and potential applications to cancer immunotherapy. Int. J. Mol. Sci. 22, 1964 (2021).","DOI":"10.3390\/ijms22041964"},{"key":"72168_CR47","doi-asserted-by":"crossref","unstructured":"Rana, P. S., Ignatz-Hoover, J. J. & Driscoll, J. J. Targeting proteasomes and the MHC class I antigen presentation machinery to treat cancer, infections and age-related diseases. Cancers 15, 5632 (2023).","DOI":"10.3390\/cancers15235632"},{"key":"72168_CR48","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1080\/15548627.2020.1769973","volume":"16","author":"K Yamamoto","year":"2020","unstructured":"Yamamoto, K., Venida, A., Perera, R. M. & Kimmelman, A. C. Selective autophagy of MHC-I promotes immune evasion of pancreatic cancer. Autophagy 16, 1524\u20131525 (2020).","journal-title":"Autophagy"},{"key":"72168_CR49","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","volume":"581","author":"K Yamamoto","year":"2020","unstructured":"Yamamoto, K. et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature 581, 100\u2013105 (2020).","journal-title":"Nature"},{"key":"72168_CR50","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.molcel.2018.12.018","volume":"73","author":"P Wu","year":"2019","unstructured":"Wu, P. et al. Mechano-regulation of peptide-MHC class I conformations determines TCR antigen recognition. Mol. Cell 73, 1015\u20131027.e1017 (2019).","journal-title":"Mol. Cell"},{"key":"72168_CR51","doi-asserted-by":"crossref","unstructured":"Vagia, E., Mahalingam, D. & Cristofanilli, M. The landscape of targeted therapies in TNBC. Cancers 12, 916 (2020).","DOI":"10.3390\/cancers12040916"},{"key":"72168_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00587-2","volume":"9","author":"NU Lin","year":"2023","unstructured":"Lin, N. U. et al. Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data. NPJ Breast Cancer 9, 94 (2023).","journal-title":"NPJ Breast Cancer"},{"key":"72168_CR53","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s43018-022-00375-0","volume":"3","author":"KK Tsai","year":"2022","unstructured":"Tsai, K. K. et al. Screening of organoids derived from patients with breast cancer implicates the repressor NCOR2 in cytotoxic stress response and antitumor immunity. Nat. Cancer 3, 734\u2013752 (2022).","journal-title":"Nat. Cancer"},{"key":"72168_CR54","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10549-012-2262-7","volume":"136","author":"CL Smith","year":"2012","unstructured":"Smith, C. L. et al. Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence. Breast Cancer Res. Treat. 136, 253\u2013265 (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"72168_CR55","doi-asserted-by":"publisher","first-page":"vi35","DOI":"10.1093\/annonc\/mds193","volume":"23","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz, G. & Martin, M. Neoadjuvant treatments for triple-negative breast cancer (TNBC). Ann. Oncol. 23, vi35\u2013vi39 (2012).","journal-title":"Ann. Oncol."},{"key":"72168_CR56","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3816\/CBC.2009.n.005","volume":"9","author":"F Kassam","year":"2009","unstructured":"Kassam, F. et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin. Breast Cancer 9, 29\u201333 (2009).","journal-title":"Clin. Breast Cancer"},{"key":"72168_CR57","first-page":"1399","volume":"52","author":"CJ Aslakson","year":"1992","unstructured":"Aslakson, C. J. & Miller, F. R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52, 1399\u20131405 (1992).","journal-title":"Cancer Res."},{"key":"72168_CR58","first-page":"20","volume":"20","author":"BA Pulaski","year":"2001","unstructured":"Pulaski, B. A. & Ostrand-Rosenberg, S. Mouse 4T1 breast tumor model. Curr. Protoc. Immunol. 20, 20\u201322 (2001).","journal-title":"Curr. Protoc. Immunol."},{"key":"72168_CR59","doi-asserted-by":"crossref","unstructured":"Arlt, M. J., Born, W. & Fuchs, B. Improved visualization of lung metastases at single cell resolution in mice by combined in-situ perfusion of lung tissue and X-Gal staining of lacZ-tagged tumor cells. J. Vis. Exp. 66, e4162 (2012).","DOI":"10.3791\/4162-v"},{"key":"72168_CR60","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1101\/gad.314617.118","volume":"32","author":"H Gonzalez","year":"2018","unstructured":"Gonzalez, H., Hagerling, C. & Werb, Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 32, 1267\u20131284 (2018).","journal-title":"Genes Dev."},{"key":"72168_CR61","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nature11428","volume":"490","author":"V Litvak","year":"2012","unstructured":"Litvak, V. et al. A FOXO3-IRF7 gene regulatory circuit limits inflammatory sequelae of antiviral responses. Nature 490, 421\u2013425 (2012).","journal-title":"Nature"},{"key":"72168_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.910705","volume":"13","author":"A Jha","year":"2022","unstructured":"Jha, A. et al. SMRT and NCoR1 fine-tune inflammatory versus tolerogenic balance in dendritic cells by differentially regulating STAT3 signaling. Front. Immunol. 13, 910705 (2022).","journal-title":"Front. Immunol."},{"key":"72168_CR63","doi-asserted-by":"publisher","first-page":"e0163521","DOI":"10.1371\/journal.pone.0163521","volume":"11","author":"M Puchalapalli","year":"2016","unstructured":"Puchalapalli, M. et al. NSG mice provide a better spontaneous model of breast cancer metastasis than athymic (nude) mice. PLoS ONE 11, e0163521 (2016).","journal-title":"PLoS ONE"},{"key":"72168_CR64","doi-asserted-by":"publisher","first-page":"14140","DOI":"10.1073\/pnas.1119842109","volume":"109","author":"Q Yan","year":"2012","unstructured":"Yan, Q. et al. Nuclear factor-kappaB binding motifs specify Toll-like receptor-induced gene repression through an inducible repressosome. Proc. Natl. Acad. Sci. USA 109, 14140\u201314145 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"72168_CR65","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.cell.2023.02.032","volume":"186","author":"J Gungabeesoon","year":"2023","unstructured":"Gungabeesoon, J. et al. A neutrophil response linked to tumor control in immunotherapy. Cell 186, 1448\u20131464 e1420 (2023).","journal-title":"Cell"},{"key":"72168_CR66","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1016\/j.cell.2021.04.016","volume":"184","author":"C Cui","year":"2021","unstructured":"Cui, C. et al. Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. Cell 184, 3163\u20133177.e3121 (2021).","journal-title":"Cell"},{"key":"72168_CR67","doi-asserted-by":"publisher","first-page":"e0188799","DOI":"10.1371\/journal.pone.0188799","volume":"12","author":"RS Berry","year":"2017","unstructured":"Berry, R. S. et al. High levels of tumor-associated neutrophils are associated with improved overall survival in patients with stage II colorectal cancer. PLoS ONE 12, e0188799 (2017).","journal-title":"PLoS ONE"},{"key":"72168_CR68","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/onc.2012.201","volume":"32","author":"MA Lopez-Lago","year":"2013","unstructured":"Lopez-Lago, M. A. et al. Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression. Oncogene 32, 1752\u20131760 (2013).","journal-title":"Oncogene"},{"key":"72168_CR69","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00262-024-03761-y","volume":"73","author":"CC Cheng","year":"2024","unstructured":"Cheng, C. C. et al. Tumor-intrinsic IFNalpha and CXCL10 are critical for immunotherapeutic efficacy by recruiting and activating T lymphocytes in tumor microenvironment. Cancer Immunol. Immunother. 73, 175 (2024).","journal-title":"Cancer Immunol. Immunother."},{"key":"72168_CR70","doi-asserted-by":"crossref","unstructured":"Reschke, R. et al. Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma. J. Immunother. Cancer 9, e003521 (2021).","DOI":"10.1136\/jitc-2021-003521"},{"key":"72168_CR71","doi-asserted-by":"publisher","first-page":"8437","DOI":"10.1158\/0008-5472.CAN-08-1440","volume":"68","author":"M Wendel","year":"2008","unstructured":"Wendel, M., Galani, I. E., Suri-Payer, E. & Cerwenka, A. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res. 68, 8437\u20138445 (2008).","journal-title":"Cancer Res."},{"key":"72168_CR72","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00262-014-1629-5","volume":"64","author":"E Wennerberg","year":"2015","unstructured":"Wennerberg, E., Kremer, V., Childs, R. & Lundqvist, A. CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo. Cancer Immunol. Immunother. 64, 225\u2013235 (2015).","journal-title":"Cancer Immunol. Immunother."},{"key":"72168_CR73","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-08-2281","volume":"69","author":"H Harlin","year":"2009","unstructured":"Harlin, H. et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 69, 3077\u20133085 (2009).","journal-title":"Cancer Res."},{"key":"72168_CR74","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1089\/107999004323065093","volume":"24","author":"SL Sague","year":"2004","unstructured":"Sague, S. L., Tato, C., Pure, E. & Hunter, C. A. The regulation and activation of CD44 by natural killer (NK) cells and its role in the production of IFN-gamma. J. Interferon Cytokine Res. 24, 301\u2013309 (2004).","journal-title":"J. Interferon Cytokine Res."},{"key":"72168_CR75","doi-asserted-by":"publisher","first-page":"d665","DOI":"10.2741\/A311","volume":"3","author":"AQ Rafi-Janajreh","year":"1998","unstructured":"Rafi-Janajreh, A. Q., Nagarkatti, P. S. & Nagarkatti, M. Role of CD44 in CTL and NK cell activity. Front. Biosci. 3, d665\u2013d671 (1998).","journal-title":"Front. Biosci."},{"key":"72168_CR76","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3389\/fimmu.2013.00395","volume":"4","author":"H Lund","year":"2013","unstructured":"Lund, H., Boysen, P., Hope, J. C., Sjurseth, S. K. & Storset, A. K. Natural killer cells in afferent lymph express an activated phenotype and readily produce IFN-gamma. Front. Immunol. 4, 395 (2013).","journal-title":"Front. Immunol."},{"key":"72168_CR77","doi-asserted-by":"publisher","first-page":"621254","DOI":"10.3389\/fimmu.2020.621254","volume":"11","author":"EE Peterson","year":"2020","unstructured":"Peterson, E. E. & Barry, K. C. The natural killer-dendritic cell immune axis in anti-cancer immunity and immunotherapy. Front. Immunol. 11, 621254 (2020).","journal-title":"Front. Immunol."},{"key":"72168_CR78","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/08830180902978120","volume":"28","author":"F Zhou","year":"2009","unstructured":"Zhou, F. Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation. Int. Rev. Immunol. 28, 239\u2013260 (2009).","journal-title":"Int. Rev. Immunol."},{"key":"72168_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09982-5","volume":"10","author":"HS Kaya-Okur","year":"2019","unstructured":"Kaya-Okur, H. S. et al. CUT&Tag for efficient epigenomic profiling of small samples and single cells. Nat. Commun. 10, 1930 (2019).","journal-title":"Nat. Commun."},{"key":"72168_CR80","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1038\/s41596-022-00692-9","volume":"17","author":"FC Grandi","year":"2022","unstructured":"Grandi, F. C., Modi, H., Kampman, L. & Corces, M. R. Chromatin accessibility profiling by ATAC-seq. Nat. Protoc. 17, 1518\u20131552 (2022).","journal-title":"Nat. Protoc."},{"key":"72168_CR81","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nri3339","volume":"12","author":"KS Kobayashi","year":"2012","unstructured":"Kobayashi, K. S. & van den Elsen, P. J. NLRC5: a key regulator of MHC class I-dependent immune responses. Nat. Rev. Immunol. 12, 813\u2013820 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"72168_CR82","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-023-01480-x","volume":"8","author":"J Yang","year":"2023","unstructured":"Yang, J. et al. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets. Signal Transduct. Target Ther. 8, 210 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"72168_CR83","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41392-023-01528-y","volume":"8","author":"R Liu","year":"2023","unstructured":"Liu, R. et al. Methylation across the central dogma in health and diseases: new therapeutic strategies. Signal Transduct. Target Ther. 8, 310 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"72168_CR84","doi-asserted-by":"crossref","unstructured":"Keshari, S., Barrodia, P. & Singh, A. K. Epigenetic perspective of immunotherapy for cancers. Cells 12, 365 (2023).","DOI":"10.3390\/cells12030365"},{"key":"72168_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01899-4","volume":"22","author":"X Wu","year":"2023","unstructured":"Wu, X. et al. Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects. Mol. Cancer 22, 194 (2023).","journal-title":"Mol. Cancer"},{"key":"72168_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17175-8","volume":"11","author":"M Hegde","year":"2020","unstructured":"Hegde, M. et al. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat. Commun. 11, 3549 (2020).","journal-title":"Nat. Commun."},{"key":"72168_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40115-1","volume":"14","author":"EHJ Lee","year":"2023","unstructured":"Lee, E. H. J. et al. Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting. Nat. Commun. 14, 4737 (2023).","journal-title":"Nat. Commun."},{"key":"72168_CR88","doi-asserted-by":"publisher","first-page":"996495","DOI":"10.3389\/fonc.2022.996495","volume":"12","author":"X Han","year":"2022","unstructured":"Han, X., Chang, W. W. & Xia, X. Immune checkpoint inhibitors in advanced and recurrent\/metastatic cervical cancer. Front. Oncol. 12, 996495 (2022).","journal-title":"Front. Oncol."},{"key":"72168_CR89","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nrurol.2017.190","volume":"15","author":"A Siefker-Radtke","year":"2018","unstructured":"Siefker-Radtke, A. & Curti, B. Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. Nat. Rev. Urol. 15, 112\u2013124 (2018).","journal-title":"Nat. Rev. Urol."},{"key":"72168_CR90","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","volume":"42","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat. Biotechnol. 42, 1693\u20131704 (2024).","journal-title":"Nat. Biotechnol."},{"key":"72168_CR91","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson, D. B., Nebhan, C. A., Moslehi, J. J. & Balko, J. M. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat. Rev. Clin. Oncol. 19, 254\u2013267 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"72168_CR92","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41416-020-01160-5","volume":"124","author":"SC Edwards","year":"2021","unstructured":"Edwards, S. C., Hoevenaar, W. H. M. & Coffelt, S. B. Emerging immunotherapies for metastasis. Br. J. Cancer 124, 37\u201348 (2021).","journal-title":"Br. J. Cancer"},{"key":"72168_CR93","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","volume":"8","author":"Q Sun","year":"2023","unstructured":"Sun, Q. et al. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct. Target Ther. 8, 320 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"72168_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06389-5","volume":"15","author":"L Meng","year":"2024","unstructured":"Meng, L. et al. Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks. Cell Death Dis. 15, 3 (2024).","journal-title":"Cell Death Dis."},{"key":"72168_CR95","doi-asserted-by":"publisher","first-page":"5945","DOI":"10.1158\/0008-5472.CAN-04-3787","volume":"65","author":"T So","year":"2005","unstructured":"So, T. et al. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res. 65, 5945\u20135952 (2005).","journal-title":"Cancer Res."},{"key":"72168_CR96","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3389\/fonc.2018.00381","volume":"8","author":"K Weidenfeld","year":"2018","unstructured":"Weidenfeld, K. & Barkan, D. EMT and stemness in tumor dormancy and outgrowth: are they intertwined processes? Front. Oncol. 8, 381 (2018).","journal-title":"Front. Oncol."},{"key":"72168_CR97","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1158\/2159-8290.CD-11-0239","volume":"2","author":"T Shibue","year":"2012","unstructured":"Shibue, T., Brooks, M. W., Inan, M. F., Reinhardt, F. & Weinberg, R. A. The outgrowth of micrometastases is enabled by the formation of filopodium-like protrusions. Cancer Discov. 2, 706\u2013721 (2012).","journal-title":"Cancer Discov."},{"key":"72168_CR98","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41388-021-02107-7","volume":"41","author":"T Bui","year":"2022","unstructured":"Bui, T. et al. Emergence of beta1 integrin-deficient breast tumours from dormancy involves both inactivation of p53 and generation of a permissive tumour microenvironment. Oncogene 41, 527\u2013537 (2022).","journal-title":"Oncogene"},{"key":"72168_CR99","doi-asserted-by":"crossref","unstructured":"Albrengues, J. et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science 361, eaao4227 (2018).","DOI":"10.1126\/science.aao4227"},{"key":"72168_CR100","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1158\/1055-9965.EPI-14-1380-T","volume":"24","author":"W Zhang","year":"2015","unstructured":"Zhang, W. et al. Functional variants in notch pathway genes NCOR2, NCSTN, and MAML2 predict survival of patients with cutaneous melanoma. Cancer Epidemiol. Biomark. Prev. 24, 1101\u20131110 (2015).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"72168_CR101","doi-asserted-by":"crossref","unstructured":"Pi, Y., Sun, F., Zhang, Z., Liu, X. & Lou, G. A novel notch-related gene signature for prognosis and immune response prediction in ovarian cancer. Medicina 59, 1277 (2023).","DOI":"10.3390\/medicina59071277"},{"key":"72168_CR102","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1172\/JCI74883","volume":"125","author":"DL Abravanel","year":"2015","unstructured":"Abravanel, D. L. et al. Notch promotes recurrence of dormant tumor cells following HER2\/neu-targeted therapy. J. Clin. Invest. 125, 2484\u20132496 (2015).","journal-title":"J. Clin. Invest."},{"key":"72168_CR103","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13018-021-02372-y","volume":"16","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. The role of Notch ligand Jagged1 in osteosarcoma proliferation, metastasis, and recurrence. J. Orthop. Surg. Res. 16, 226 (2021).","journal-title":"J. Orthop. Surg. Res."},{"key":"72168_CR104","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1210\/mend.11.6.0002","volume":"11","author":"H Shibata","year":"1997","unstructured":"Shibata, H., Nawaz, Z., Tsai, S. Y., O\u2019Malley, B. W. & Tsai, M. J. Gene silencing by chicken ovalbumin upstream promoter-transcription factor I (COUP-TFI) is mediated by transcriptional corepressors, nuclear receptor-corepressor (N-CoR) and silencing mediator for retinoic acid receptor and thyroid hormone receptor (SMRT). Mol. Endocrinol. 11, 714\u2013724 (1997).","journal-title":"Mol. Endocrinol."},{"key":"72168_CR105","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.molcel.2013.10.022","volume":"52","author":"Z Sun","year":"2013","unstructured":"Sun, Z. et al. Deacetylase-independent function of HDAC3 in transcription and metabolism requires nuclear receptor corepressor. Mol. Cell 52, 769\u2013782 (2013).","journal-title":"Mol. Cell"},{"key":"72168_CR106","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"72168_CR107","first-page":"71","volume":"3","author":"X Rao","year":"2013","unstructured":"Rao, X., Huang, X., Zhou, Z. & Lin, X. An improvement of the 2^(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat. Bioinform. Biomath. 3, 71\u201385 (2013).","journal-title":"Biostat. Bioinform. Biomath."},{"key":"72168_CR108","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020107333","volume":"40","author":"B Pal","year":"2021","unstructured":"Pal, B. et al. A single-cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast. EMBO J. 40, e107333 (2021).","journal-title":"EMBO J."},{"key":"72168_CR109","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"72168_CR110","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847\u20132849 (2016).","journal-title":"Bioinformatics"},{"key":"72168_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-01127-3","volume":"11","author":"W Wu","year":"2021","unstructured":"Wu, W., Howard, D., Sibille, E. & French, L. Differential and spatial expression meta-analysis of genes identified in genome-wide association studies of depression. Transl. Psychiatry 11, 8 (2021).","journal-title":"Transl. Psychiatry"},{"key":"72168_CR112","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41588-020-0610-9","volume":"52","author":"J Bryois","year":"2020","unstructured":"Bryois, J. et al. Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson\u2019s disease. Nat. Genet. 52, 482\u2013493 (2020).","journal-title":"Nat. Genet."},{"key":"72168_CR113","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1084\/jem.20151665","volume":"213","author":"TS Chan","year":"2016","unstructured":"Chan, T. S. et al. Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells. J. Exp. Med. 213, 2967\u20132988 (2016).","journal-title":"J. Exp. Med."},{"key":"72168_CR114","doi-asserted-by":"publisher","first-page":"e1268310","DOI":"10.1080\/2162402X.2016.1268310","volume":"6","author":"ET Gross","year":"2017","unstructured":"Gross, E. T. et al. Immunosurveillance and immunoediting in MMTV-PyMT-induced mammary oncogenesis. Oncoimmunology 6, e1268310 (2017).","journal-title":"Oncoimmunology"},{"key":"72168_CR115","doi-asserted-by":"crossref","unstructured":"Zawati, I. et al. Can residual proliferative cancer burden predict long-term outcomes following neoadjuvant chemotherapy in breast cancer? Pathology 57, 570\u2013578 (2025).","DOI":"10.1016\/j.pathol.2024.11.014"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72168-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72168-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72168-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:04:31Z","timestamp":1783641871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72168-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":115,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["72168"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-72168-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.03.10.642060","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Unrelated to the work herein, E.S. is a paid consultant to Guidepoint Global, Gerson Lehrman Group (GLG), FirstThought, PathAI, CapitalOneSecurities, Boxer Capital, Health Advances, Forbion, Capvision, and Insighter. He receives institutional research funding from MacroGenics, Inc and AstraZeneca. The other authors have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6067"}}